http://apjai-journal.org/wp-content/uploads/2020/03/5_AP-200220-0773.pdf
This article discusses how monoclonal antibody treatments for other strains of COVID, SARS-CoV and MERS-CoV can inform future treatments for COVID-19. Monoclonal antibodies are antibodies cloned from one parent cell that all bind to the same thing; essentially antibodies specifically against COVID-19. The study concludes that while monoclonal antibodies are a promising treatment for COVID-19, they aren’t currently a reasonable solution due to the labor intensive nature of manufacturing them; it couldn’t be done on a large enough scale to work. However, they are working on more cost effective methods that might help this be successful for future diseases.